These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 746249)

  • 41. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
    Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
    Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical staging and therapeutic results in multiple myeloma.
    Santoro A; Schieppati G; Franchi F; Valagussa P; Monfardini S
    Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1353-9. PubMed ID: 6685627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China.
    Wang X; He P; Guo C; Sun C; Zhang M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e408-e415. PubMed ID: 27739213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy for multiple myeloma.
    Alexanian R; Dreicer R
    Cancer; 1984 Feb; 53(3):583-8. PubMed ID: 6362819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
    Cooper MR; McIntyre OR; Propert KJ; Kochwa S; Anderson K; Coleman M; Kyle RA; Prager D; Rafla S; Zimmer B
    J Clin Oncol; 1986 Sep; 4(9):1331-9. PubMed ID: 3528403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
    Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Value of protocols of alternating chemotherapy versus melphalan-prednisone during the induction phase of stage III myelomas. Critical review].
    Paule B; Medicis P; Clerc D; Bennet P; Bisson M; Massias P
    Rev Rhum Mal Osteoartic; 1987 Dec; 54(12):827-32. PubMed ID: 3324290
    [No Abstract]   [Full Text] [Related]  

  • 49. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
    Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
    Lancet; 2007 Oct; 370(9594):1209-18. PubMed ID: 17920916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience.
    Cohen HJ; Bartolucci A
    Am J Med; 1985 Sep; 79(3):316-24. PubMed ID: 3898836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma.
    Cuttner J; Wasserman LR; Martz G; Sonntag RW; Kyle RA; Silver RT; Spurr C; Harley JB; Wiernik PM; Cornwell GG; Falkson G; Glidewell O; Holland JF
    Med Pediatr Oncol; 1975; 1(3):207-16. PubMed ID: 1232529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
    Wutke K; Anger G
    Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vindesine in refractory multiple myeloma.
    van der Lelie H; Monasch E; Pegels HG; von dem Borne AE
    Cancer; 1986 Jan; 57(2):226-9. PubMed ID: 3942957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.
    Ahre A; Björkholm M; Mellstedt H; Brenning G; Engstedt L; Gahrton G; Gyllenhammar H; Holm G; Johansson B; Järnmark M
    Cancer Treat Rep; 1984 Nov; 68(11):1331-8. PubMed ID: 6388832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
    MacLennan IC; Chapman C; Dunn J; Kelly K
    Lancet; 1992 Jan; 339(8787):200-5. PubMed ID: 1346171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic factors for multiple myeloma in the dog.
    Matus RE; Leifer CE; MacEwen EG; Hurvitz AI
    J Am Vet Med Assoc; 1986 Jun; 188(11):1288-92. PubMed ID: 3721983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
    Mineur P; Ménard JF; Le Loët X; Bernard JF; Grosbois B; Pollet JP; Azais I; Laporte JP; Doyen C; De Gramont A; Wetterwald M; Euller-Ziegler L; Peny AM; Monconduit M; Michaux JL
    Br J Haematol; 1998 Nov; 103(2):512-7. PubMed ID: 9827927
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Assessment of a nitrosurea combined with cyclophosphamide and prednisone versus melphalan and prednisone in the treatment of multiple myeloma (author's transl)].
    Bezares R; Bomchil G; Saslavsky J; Pavlovsky S; Curutchet M; Quiroga Micheo E; Macchi A; Musso A; Suárez A; Pizzolato M
    Sangre (Barc); 1979; 24(3):241-51. PubMed ID: 472966
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.